Discovering Promising US Penny Stocks In November 2024

In This Article:

The U.S. stock market continues to show resilience, with the S&P 500 and Nasdaq Composite experiencing gains as part of an ongoing rally, while the Dow Jones Industrial Average sees mixed performance amid varied earnings reports. Despite being viewed as a relic from past trading eras, penny stocks remain relevant by offering potential growth opportunities through smaller or newer companies with strong financials. In this article, we explore several promising penny stocks that combine affordability with robust fundamentals, presenting potential hidden gems for investors seeking value in today's market landscape.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.79

$6.1M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$143.12M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

RLX Technology (NYSE:RLX)

$1.83

$2.29B

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.2376

$8.57M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.40

$557.36M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.55

$51.15M

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8999

$80.04M

★★★★★☆

Safe Bulkers (NYSE:SB)

$4.08

$445.26M

★★★★☆☆

Click here to see the full list of 720 stocks from our US Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Puma Biotechnology

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Puma Biotechnology, Inc. is a biopharmaceutical company that develops and commercializes cancer care products in the United States and internationally, with a market cap of approximately $147.26 million.

Operations: The company generates $243.57 million from the development and commercialization of innovative cancer care products.

Market Cap: $147.26M

Puma Biotechnology has shown significant earnings growth, with a 525.3% increase over the past year, surpassing its five-year average growth rate of 62.7% annually. The company reported third-quarter revenue of US$80.54 million, up from US$56.1 million the previous year, and net income rose to US$20.32 million from US$5.8 million, reflecting improved profit margins and high-quality earnings despite recent shareholder dilution by 3.2%. With reduced debt levels and strong cash flow coverage, Puma's financial health is stable as it advances clinical trials for alisertib in metastatic breast cancer treatment.